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Background: Endoscopic resection (ER) is emerging as a curative technique in patients with high-grade
dysplasia (HGD), intramucosal cancer (IMC), and early submucosal cancer (T1sm1) within Barrett's
oesophagus. Methods: This consecutive case series of 72 patients with HGD or IMC reports outcomes of
ER, with or without mucosal ablation, in a single institution after a median of 38 months follow-up
between 2004 and 2011. The primary outcome was disease progression to submucosal invasion. Sec-
ondary outcomes included disease regression, the effect of ER on staging compared to biopsy and
procedure-related complications. Results: 72 patients (mean age 73.0 e range 52.0e93.0) were treated
by ER ± ablative therapy with curative intent for HGD (88% patients) or IMC (12%). 38% had one or more
severe systemic co-morbidities. A median of 4 (1e11) procedures were undertaken per patient. In
addition to ER, 43% of patients were treated with argon plasma coagulation, 17% with radiofrequency
ablation, and 11% with photodynamic therapy. 8 (13%) patients with HGD at baseline and 0 (0%) with IMC
progressed to invasive carcinoma. The median time to progression was 26.3 and 12.6 months respec-
tively. 51% patients experienced disease regression. Disease staging was upgraded by ER in 27% of pa-
tients. Discussion: This case series reports on a minimally invasive technique in an elderly population
with multiple co-morbidities, demonstrating disease regression with long-term follow-up. Conclusion:
ER ± ablation is an effective and potentially curative option for patients with HGD or IMC. The beneﬁt of
endoscopic resection for disease staging was clearly demonstrated.
© 2014 Surgical Associates Ltd. Published by Elsevier Ltd. All rights reserved.1. Introduction
The incidence of oesophageal adenocarcinoma has increased by
500% over the past 30 years [1]. Barrett's oesophagus is a known
risk factor for the development of adenocarcinoma and classically
progresses to malignancy through a sequential series of dysplastic
phases characterised histologically as low-grade dysplasia and, zoe.oliphant@tst.nhs.uk
by Elsevier Ltd. All rights reservedhigh-grade dysplasia (HGD). Recently endoscopic techniques have
emerged which can enable curative treatment of high-grade
dysplasia (HGD) and prevent progression to adenocarcinoma. In
addition, endoscopic therapy can also treat early intramucosal
cancer (IMC) since T1a tumours rarely metastasise to lymph nodes
(<5%) and therefore complete excision may be possible by endo-
scopic resection without the need for routine lymphadenectomy
[2e4].
Although endotherapies are now widely practised, there re-
mains little published long-term follow-up data, particularly
outside of clinical trials, and the natural history of endoscopically.
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reports early experience of endoscopic therapy from a regional UK
unit. Long-term follow-up of patients with Barrett's-associated
HGD and IMC treated by ER alone or in combination with endo-
scopic ablation are presented.
2. Methods
This retrospective observational case series reviewed data from
patients with biopsy proven Barrett's-associated HGD and/or IMC
treated with therapeutic intent by ER with or without mucosal
ablation between 2004 and 2011. All patients were treated at a
single UK Regional Referral Centre serving a population of 1.2
million people from four satellite hospitals. Sporadic referrals from
other areas in the UK and overseas were also received.
A retrospective database was compiled following meticulous
abstraction of data from written and electronic case notes.
Following MDT discussion endotherapy was performed for HGD
and IMC in patients that were deemed unsuitable or high-risk for
radical surgical intervention. EMR was used alone, or in combina-
tion with mucosal ablation. Resection and ablation techniques
varied throughout the study period reﬂecting changes in practice.
Ablation modalities included photodynamic therapy (PDT), argon
plasma coagulation (APC) and radiofrequency ablation (RFA).
Following initial ER patients were re-scoped at 8 weeks with
further resection of any new or recurrent visible lesions. Ablation
therapy was applied to the whole Barrett's segment when there
was no further evidence of macroscopic dysplasia but persistent
visible columnar epithelium.
All patients were followed-up for at least 12 months. Patients
with squamous dysplasia and patients with incomplete follow-up
data were excluded.
The primary outcome measure was the proportion of patients
undergoing ER with or without ablative therapy that progressed to
submucosal invasion or beyond. Secondary outcomes included the
proportion of patients that underwent disease regression and the
effect of EMR on staging compared to biopsy. Complications of
endoscopic therapy are also reported.
The presence of severe systemic co-morbidities was deﬁned as
those that would qualify as Grade 3 on the ASA (American Society of
Anaesthesiologists) physical status classiﬁcation system. This
included coronary artery disease, diabetes, atrial ﬁbrillation,




72 patients, 63 (87.5%) with HGD and 9 (12.5%) with IMCmet the
inclusion criteria (Table 1). Their mean age was 73 years (range
52e93 years) and 59 (82%) weremale. Themedian length of follow-
up was 38 months (range 12 monthse7 years). 27 (37.5%) patients
had one or more severe systemic co-morbidities.Table 1
Patient demographics.
Study population n ¼ 72 patients
Age Median 73 years (range 52e93 yrs)
Major coemorbidities n ¼ 27 (37.5%)
Diagnosis HGD: n ¼ 63 (87.5%)
IMC: n ¼ 9 (12.5%)
Male/female M ¼ 59 (80%); F ¼ 15
Followeup Median 38 months (range 12 monthse7 years)3.2. Endoscopic therapy
A median of 4 (1e11) procedures were undertaken per patient.
29 (40%) patients were treated by ER alone. In addition to ER, 43% of
patients were treated with argon plasma coagulation, 17% with
radiofrequency ablation, and 11% with photodynamic therapy. The
use of ablative therapies changed as clinical practice evolved during
the study period.
3.3. Disease speciﬁc outcomes
Of the 72 patients that satisﬁed the inclusion criteria, 37 (51%)
saw regression of their disease. 22 (30%) patients, 3 with IMC and
19 with HGD, had stable disease without evidence of progression
throughout the duration of the study period (Table 2).
Dysplasia was completely eradicated (CE-D) with reversion to
non-dysplastic Barrett's in 21 (29%) patients. 8 (13%) patients with
HGD and 1 (%) patient with intra-mucosal cancer regressed to low-
grade dysplasia. Complete eradication of intestinal metaplasia (CE-
IM) was achieved in 1 (1.4%) patient with a baseline diagnosis of
HGD. Overall disease regression was achieved in 28 (44%) patients
with HGD and 7 (38%) patients with IMC.
Eight (12.7%) patients with HGD progressed to submucosal
carcinoma over a median time of 31 months (Fig. 1). All were
considered for oesophagectomy but 4 were either deemed unﬁt for
surgery or chose conservative management. 4 patients underwent
successful Ivor-Lewis oesophagectomy.
3.4. Procedure-related morbidity
One (1.2%) patient suffered an oesophageal perforation
following ER. This patient made a successful recovery following
conservative management. 6 (8%) patients developed post-
procedural oesophageal strictures requiring dilatation. There
were no procedure-related deaths and no patients required surgical
intervention as a result of an endoscopic complication.
3.5. Comparison of histology on ER and biopsy
37 patients (26 with HGD; 2 with IMC; 5 with LGD) underwent
ER within 3 months of initial baseline biopsy. ER modiﬁed disease
staging in 11 (30%) patients; up-staging in 10 (27%), down-staging
in 1 (3%).
Of those that had their disease up-staged 5 (14%) had their
diagnosis changed fromHGD to IMC, and 1 (3%) had HGD up-staged
to SMC. The patient that was down-staged had their diagnosis
amended from HGD to non-dysplastic Barrett's oesophagus.
4. Discussion
This single-centre case series reports long-term outcomes of
endoscopic therapy for HGD and IMC in an elderly group of pa-
tients, with a high rate of signiﬁcant medical co-morbidities. After a
median follow-up of 38 months the use of ER with or without
adjuvant ablation therapy eradicated dysplasia in 43% of patientsTable 2
Comparison of baseline diagnosis with post-endotherapy ﬁnal diagnosis after a
median follow-up of 38 months.
Initial diagnosis Final diagnosis
Normal Barretts LGD HGD IMC SMC invasion or beyond
HGD (n ¼ 63) 1 15 8 19 3 8
IMC (n ¼ 9) 0 6 1 8 3 0
Fig. 1. A Kaplan Meier plot illustrating the time taken for progression from HGD to
invasive adenocarcinoma in the 8 patients who progressed despite endoscopic therapy.
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shown to alter disease staging in 30% of patients. Endoscopic
therapy was performed with low morbidity and no procedure-
related mortality.
Modern series frequently report higher rates of CE-IM and CE-D
than the present study [5,6]. This may reﬂect several factors
including the current widespread use of 360 RFA, which now has a
well-established evidence base, the standard use of combination
endotherapy (typically ER and RFA), and the recent recommenda-
tion for whole segment ablation after resection of focal lesions [7,8].
In addition, the present study included patients with widespread
multifocal HGD who were unﬁt for oesophagectomy. It is possible
that these patients harboured malignant disease which was under-
staged, particularly in the early years of the study when endoscopic
ultrasound was not routinely available.
A recent international consensus statement on themanagement
of Barrett's dysplasia reported that a majority of expert clinicians
support the policy of focal lesion resection using ER followed by
whole Barrett's segment ablation to destroy the neoplastic oeso-
phageal ﬁeld change [8]. However, to date, few studies have re-
ported outcomes of combination ER and ablation, and follow-up
periods have been short. The present study highlights the impor-
tance of long-term follow-up and meticulous auditing of patient
outcomes. The natural history of endoscopically treated dysplastic
Barrett's oesophagus remains unclear and as a result UK and US
guidelines recommend surveillance biopsy even where there has
been complete eradication of intestinal metaplasia. The incidence
of buried adenocarcinoma occurring below a neosquamous
epithelium appears rare although is well documented [9].
There are several limitations which must be acknowledged. This
is a retrospective study reliant on review of case notes and elec-
tronic records. In addition, there was signiﬁcant loss to follow-up,
particularly associated with out-of-area referrals since changes in
local funding during the study period meant a number of patients'
care was transferred to other tertiary centres. The number of
included patients was insufﬁcient to allow meaningful comparison
of patients treated by ER alone to those who also received ablation
therapy. Finally, since this was not a controlled trial it was not
possible to calculate the number-needed-to treat to prevent pro-
gression to malignancy or the median survival beneﬁt achieved by
endoscopic therapy.
Endoscopic therapy is now widely available and recommended
for patients with HGD as a ﬁrst line treatment option [10]. Despitethis, there is little available data reporting long-term outcomes and
the natural history of ablated Barrett's oesophagus remains unclear.
In addition, most published outcomes are reports of clinical trials
rather than audits of clinical practice. It is essential that units
actively collect and prospectively monitor outcomes of endoscopic
therapy in order to evaluate real the clinical effectiveness of this
emerging therapy.Ethical approval
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